T-Net: Home

Member Login
|
Employer Login

BC Tech News ▼
International ▼
Member Tools ▼
- Subscribe to T-Net Direct
Submit News ▼

« Sections »
News
Events
Tech Careers
Directory
Tech Stocks
T-Net 100
Members
Feedback
About T-Net
« Account Login »
Members
Employers
« Services »
Post Job Listings
Browse Jobs
Advertise

News By Company

NervGen Pharma Corp.

1 - 7 of 7 Results

New Search

NervGen Pharma Appoints Former Pfizer Executive Craig Thompson to its Board of Directors

Vancouver, BC, April 18, 2022--NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF), a clinical stage biotech company developing a first-in-class neuroreparative drug to treat nervous system damage, announced the appointment of Craig Thompson to NervGen's Board of Directors.

Snapshot | Profile | News (8) | Follow

Company Snapshot

NervGen Pharma Corp.

Vancouver (Biotech/Life Sciences)
10-19 Employees In BC (10-19 Employees Total)
Founded: 2017

NervGen is a publicly traded (TSX-V: NGEN, OTCQX: NGENF) clinical stage biotech company dedicated to discovering and developing treatments for patients suffering from medical conditions related to nerve damage, either as a result of injury, neurodeg

See Full Profile

Company Alert

NervGen Pharma Corp.

Vancouver (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

NervGen Presenting Interim Phase 1 Clinical Trial Data for NVG-291 at the 2022 American Academy of Neurology Annual Meeting

Vancouver, BC, April 13, 2022--NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF), a clinical stage biotech company dedicated to developing a first-in-class neuroreparative drug to treat nervous system damage, announced that it will provide an update on its Phase 1 program with NVG-291 in healthy volunteers at the 2022 American Academy of Neurology Annual Meeting.

Snapshot | Profile | News (8) | Follow

Company Snapshot

See Full Profile

Company Alert

NervGen Pharma Corp.

Vancouver (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

NervGen Pharma Receives Approval from Safety Review Committee to Proceed to Second Cohort in Multiple Ascending Dose Portion of Phase 1 Clinical

Vancouver, BC, March 29, 2022--NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, has received approval from the Safety Review Committee to advance to the second cohort in the multiple ascending dose (MAD) portion of its Phase 1 clinical trial of the Company's proprietary lead compound, NVG-291.

Snapshot | Profile | News (8) | Follow

Company Snapshot

See Full Profile

Company Alert

NervGen Pharma Corp.

Vancouver (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

NervGen Pharma Reports 2021 Year End Results and Provides Update on Phase 1 Study

Vancouver, BC, March 9, 2022--NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, reported its financial and operational results for the year ended December 31, 2021.

Snapshot | Profile | News (8) | Follow

Company Snapshot

See Full Profile

Company Alert

NervGen Pharma Corp.

Vancouver (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

NervGen Pharma Announces Intent to Conduct Groundbreaking Spinal Cord Injury Clinical Trial in Exclusive Partnership With Shirley Ryan AbilityLab

Vancouver, BC, January 14, 2022--NervGen Pharma Corp., (TSX-V: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, announced it has entered into a Memorandum of Understanding with Shirley Ryan AbilityLab with the intention of performing NervGen's first clinical trial with the Company's proprietary NVG-291 in spinal cord injury (SCI) patients.

Snapshot | Profile | News (8) | Follow

Company Snapshot

See Full Profile

Company Alert

NervGen Pharma Corp.

Vancouver (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

NervGen Pharma Receives Ethics Board Approval for Multiple Ascending Dose Portion of NVG-291 Phase 1 Trial

Vancouver, BC, January 5, 2022--NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to creating innovative treatments that repair nervous system damage, announced it has received ethics board approval from Bellberry Limited's Human Research Ethics Committee (HREC) to proceed with the multiple ascending dose (MAD) portion of its Phase 1 trial with its lead compound, NVG-291.

Snapshot | Profile | News (8) | Follow

Company Snapshot

See Full Profile

Company Alert

NervGen Pharma Corp.

Vancouver (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Vancouver-based NervGen Pharma Partners with Imeka to Use Novel Neuroimaging Technology in Clinical Trials

Vancouver, BC, October 27, 2021--NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage announced a partnership with Imeka Solutions Inc., currently the only neuroimaging company that combines artificial intelligence and diffusion imaging to obtain high resolution images of white matter in the brain.

Snapshot | Profile | News (8) | Follow

Company Snapshot

See Full Profile

Company Alert

NervGen Pharma Corp.

Vancouver (Biotech/Life Sciences)

Notify Me

New Job Listings Posted By This Company
News and Editorial Regarding This Company
Company Profile Changes and Updates
Personnel Changes At This Company

Company Alert Notification Settings

Please select how you would like to be notified of updates by this Company:

	Display Updates For This Company in My Member Account Online
	Please Send me an Email Alert (With All of My Company Updates) On The Following Dates:
	(Updates from all selected companies are combined and sent in a single email)

Cancel

Hiring Today

See All Jobs

Latest Tech Jobs

Featured Job: Solutions Architect Lead

Insurance Corporation of BC

Intermediate/Senior Paralegal

Tantalus Systems Corp.

Junior Software Development Engineer in Test

Global Relay Communications Inc.

Service Design Lead

BC Public Service

Engineering Services Clerk 3

BC Hydro

See All Jobs

Registration on or use of this website constitutes acceptance of our Terms of Use.

News
BC Tech News ▼
- Local BC Tech News
- One Week View
- Subscribe to T-Net Direct
International ▼
- All Breaking International Tech News
- Tech Crunch
- Silicon Alley Insider
- VentureBeat
- CNET
Member Tools ▼
- Subscribe to T-Net Direct
Submit News ▼
- Post News Release on T-Net
- Submit Anonymous News Tip
- T-Net News Submission Guidelines
Account
Member Login
Employer Login
Sections
News
- BC Tech News ▼
- International ▼
- Member Tools ▼
  - Subscribe to T-Net Direct
- Submit News ▼
Events
- All BC Tech Events ▼
- Member Tools ▼
- Post Events ▼
Tech Careers
- Tech Careers Home
- Job Search ▼
- Hot Job of the Week TM
- Post Resume ▼
  - Post Resume
  - Create Cover Letter
- Member Tools ▼
- Employers ▼
  - Employer Login
  - Post New Job
Directory
- Tech Directory Home
- Companies ▼
- Suppliers ▼
- Associations ▼
- Add Profile ▼
Tech Stocks
- BC Tech Stocks ▼
- T-Net 20 Stock Index
- Member Tools ▼
  - Stock Alerts
  - Company Search
- Add Company ▼
  - Add Company
T-Net 100
- T-Net 100 Rankings ▼
- Sector Rankings ▼
- Advertising
Members
- Member Home ▼
- News ▼
- Events ▼
- Careers ▼
- Directory ▼
- Other ▼
Feedback
About T-Net
Services
Post Job Listings
Advertise on T-Net